Optimization of PK/PD Target Attainment for Meropenem in Critically Ill Patients With Sepsis
NCT ID: NCT03560557
Last Updated: 2021-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
116 participants
OBSERVATIONAL
2012-08-31
2017-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units
NCT02213796
Efficacy and Pharmacokinetics of Meropenem in Severe Septic Patients
NCT03645668
Citrate Versus Heparin Anticoagulation: Effect on Molecules Clearances
NCT01839578
Identification of Cardiovascular and Molecular Prognostic Factors for the Mid- and Long-term Outcome of Sepsis
NCT03620409
Left Ventricular Unloading to Improve Outcome in Cardiogenic Shock Patients on VA-ECMO
NCT05577195
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Second, the investigators will try to identify risk factors for not attaining PK/PD target. Based on significant predictors for target non attainment a predictive dosing algorithm will be constructed.
Finally in a small subset of ECMO patients PK exposure will be explored.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admitted to an ICU ward
* Treated with meropenem
Exclusion Criteria
* Renal replacement therapy
* Pregnancy
* DNR code 1-3
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitaire Ziekenhuizen KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Matthias Gijsen
PharmD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Isabel Spriet, PharmD PhD
Role: STUDY_DIRECTOR
UZ Leuven
References
Explore related publications, articles, or registry entries linked to this study.
Gijsen M, Elkayal O, Annaert P, Van Daele R, Meersseman P, Debaveye Y, Wauters J, Dreesen E, Spriet I. Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function. Infect Drug Resist. 2022 Jan 8;15:53-62. doi: 10.2147/IDR.S343264. eCollection 2022.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML8459
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.